The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with chemotherapy and with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumors express PD-L1 (CPS ≥1).
The Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of Cabometyx (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma, refractory or not eligible to radioactive iodine, who have progressed during or after prior systemic therapy.
The Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the European Commission to approve Kymriah (tisagenlecleucel), a CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Thermo Fisher Scientific launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated next-generation sequencing platform that delivers results in as soon as 24 hours.
Paige launched an AI medical device software called Paige Breast Lymph Node that helps pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review.
The National Cancer Institute approved the following clinical research studies last month. For further information, contact the principal investigator listed. Phase I – 10449 A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer University of Texas MD Anderson Cancer Center LAOPiha-Paul,... […]
James Allison has reshaped cancer drug development, making checkpoint inhibitors a staple of therapy in many key indications—and dramatically improving survival outcomes in previously recalcitrant diseases.
Cancer mortality fell by 2.1% between 2018 and 2019, compared to a 2.4% relative decrease in the year prior, according to the American Cancer Society’s 2022 Cancer Statistics report.
The rapid acceleration of drug development has exponentially increased the therapeutic options available to patients with cancer.
With the Russian invasion stalled and with a forceful counter-attack by Ukrainian armed forces, many observers caution that the Kremlin might be considering a show of force much as the U.S. did in the atomic bombings of Hiroshima and Nagasaki (The Cancer Letter, Feb. 25, March 4, March 11, 2022).
